Background and Purpose: To assess the validity of the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE) in the detection of vascular mild cognitive impairment (VaMCI) in patients with subcortical ischemic vascular disease (SIVD). Methods: Among 102 SIVD patients, both cutoff scores of the MMSE and MoCA for differentiating VaMCI from no cognitive impairment (NCI) or differentiating VaMCI from vascular dementia (VaD) were determined by the receiver operator characteristic (ROC) analysis. Optimal sensitivity with specificity of cutoff scores was obtained after the raw scores were adjusted for education. Results: After adjusting for education, the MoCA cutoff score for differentiating VaMCI from NCI was at 24/25 and that for differentiating VaMCI from VaD was at 18/19. After applying the adjusted MoCA scores from 19 to 24 to identify VaMCI in all SIVD patients, sensitivity was at 76.7% and specificity was at 81.4% (κ = 0.579). The adjusted cutoff score of the MMSE for differentiating VaMCI from NCI was at 28/29 and that for differentiating VaMCI from VaD was at 25/26. The sensitivity and specificity of the adjusted MMSE was at 58.1 and 71.2%, respectively, when using the score from 26 to 28 to identify VaMCI in SIVD patients (κ = 0.294). Conclusions: The MoCA detected subcortical VaMCI better than the MMSE.

Keywords:
Vascular cognitive impairment, Mild cognitive impairment , Subcortical ischemic vascular disease, Mini-Mental State Examination, Montreal Cognitive Assessment
1.
Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al, American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia: Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2672-2713.
2.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
3.
Tombaugh TN, McIntyre NJ: The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc 1992;40:922-935.
4.
Blake H, McKinney M, Treece K, Lee E, Lincoln NB: An evaluation of screening measures for cognitive impairment after stroke. Age Ageing 2002;31:451-456.
5.
Srikanth V, Thrift AG, Fryer JL, Saling MM, Dewey HM, Sturm JW, et al: The validity of brief screening cognitive instruments in the diagnosis of cognitive impairment and dementia after first-ever stroke. Int Psychogeriatr 2006;18:295-305.
6.
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
7.
Fujiwara Y, Suzuki H, Yasunaga M, Sugiyama M, Ijuin M, Sakuma N, et al: Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int 2010;10:225-232.
8.
Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al: National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006;37:2220-2241.
9.
Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al: Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23-30.
10.
Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC: Subcortical ischemic vascular dementia. Lancet Neurol 2002;1:426-436.
11.
Moorhouse P, Rockwood K: Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol 2008;7:246-255.
12.
Chui H: Dementia due to subcortical ischemic vascular disease. Clin Cornerstone 2001;3:40-51.
13.
Galluzzi S, Sheu CF, Zanetti O, Frisoni GB: Distinctive clinical features of mild cognitive impairment with subcortical cerebrovascular disease. Dement Geriatr Cogn Disord 2005;19:196-203.
14.
Pantoni L, Basile AM, Pracucci G, Asplund K, Bogousslavsky J, Chabriat H, et al: Impact of age-related cerebral white matter changes on the transition to disability - the LADIS study: rationale, design and methodology. Neuroepidemiology 2005;24:51-62.
15.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
16.
Zhang MY: Guideline of Psychiatrical Scales. Changsha, Human Science and Technology Press, 1993.
17.
Wen HB, Zhang ZX, Niu FS, Li L: The application of Montreal cognitive assessment in urban Chinese residents of Beijing. Chin J Int Med 2008;47:36-39.
18.
Guo QH, Sun YM, Yuan J, Hong Z, Lu CZ: Application of eight executive tests in participants at Shanghai communities. Chin J Behav Med Sci 2007;16:628-631.
19.
Sun YM, Guo QH, Yuan J, Hong Z, Lu CZ: The norms and the cut off scores of four fluency tests in the middle aged and the old in Shanghai communities. Chin J Behav Med Sci 2007;16:714-717.
20.
Guo QH, Sun YM, Yu PM, Hong Z, Lu CZ: Norms for Auditory Verbal Learning Test in the normal aged in Chinese community. Chin J Clin Psychol 2007;15:132-135.
21.
Guo QH, Zhao QH, Chen MR, Ding D, Hong Z: A comparison study of mild cognitive impairment with 3 memory tests among Chinese individuals. Alzheimer Dis Assoc Disord 2009;23:253-259.
22.
Zhou Y, Lu JC, Guo QH, Hong ZN: Rey-Osterrieth complex figure test used to identify mild Alzheimer's disease. Chin J Clin Neurosci 2006;14:501-504.
23.
Guo QH, Hong Z, Shi WX, Sun YM, Lu CZ: Boston naming test using by Chinese elderly patient with mild cognitive impairment and Alzheimer's dementia. Chinese Mental Health J 2006;20:81-85.
24.
Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW: Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. J Am Med Assoc 1963;185:914-919.
25.
Lawton MP, Brody EM: Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
26.
Xu Q, Zhou Y, Li YS, Cao WW, Lin Y, Pan YM, et al: Diffusion tensor imaging changes correlate with cognition better than conventional MRI findings in patients with subcortical ischemic vascular disease. Dement Geriatr Cogn Disord 2010;30:317-326.
27.
Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.
28.
Jellinger KA: The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 2007;113:349-388.
29.
Jokinen H, Kalska H, Mäntylä R, Pohjasvaara T, Ylikoski R, Hietanen M, et al: Cognitive profile of subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 2006;77:28-33.
30.
Dong Y, Sharma VK, Chan BP, Venketasubramanian N, Teoh HL, Seet RC, et al: The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci 2010;299:15-18.
31.
Pendlebury ST, Cuthbertson FC, Welch SJ, Mehta Z, Rothwell PM: Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke 2010;41:1290-1293.
32.
Pendlebury ST, Mariz J, Bull L, Mehta Z, Rothwell PM: MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke. Stroke 2012;43:464-469.
33.
Pendlebury ST, Markwick A, de Jager CA, Zamboni G, Wilcock GK, Rothwell PM: Differences in cognitive profile between TIA, stroke and elderly memory research subjects: a comparison of the MMSE and MoCA. Cerebrovasc Dis 2012;34:48-54.
34.
Ihara M, Okamoto Y, Takahashi R: Suitability of the Montreal cognitive assessment versus the mini-mental state examination in detecting vascular cognitive impairment. J Stroke Cerebrovasc Dis 2013;22:737-741.
35.
Kasai M, Meguro K, Nakamura K, Nakatsuka M, Ouchi Y, Tanaka N: Screening for very mild subcortical vascular dementia patients aged 75 and above using the Montreal Cognitive Assessment and Mini-Mental State Examination in a community: the Kurihara Project. Dement Geriatr Cogn Disord Extra 2012;2:503-515.
36.
Wong A, Xiong YY, Kwan PW, Chan AY, Lam WW, Wang K, et al: The validity, reliability and clinical utility of the Hong Kong Montreal Cognitive Assessment (HK-MoCA) in patients with cerebral small vessel disease. Dement Geriatr Cogn Disord 2009;28:81-87.
37.
Freitas S, Simões MR, Alves L, Vicente M, Santana I: Montreal cognitive Assessment (MoCA): validation study for vascular dementia. J Int Neuropsychol Soc 2012;18:1031-1040.
38.
Godefroy O, Fickl A, Roussel M, Auribault C, Bugnicourt JM, Lamy C, et al: Is the Montreal Cognitive Assessment superior to the Mini-Mental State Examination to detect poststroke cognitive impairment? A study with neuropsychological evaluation. Stroke 2011;42:1712-1716.
39.
Lee JY, Dong Woo L, Cho SJ, Na DL, Hong Jin J, Kim SK, et al: Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol 2008;21:104-110.
40.
Luis CA, Keegan AP, Mullan M: Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the southeastern US. Int J Geriatr Psychiatry 2009;24:197-201.
41.
Damian AM, Jacobson SA, Hentz JG, Belden CM, Shill HA, Sabbagh MN, et al: The Montreal Cognitive Assessment and the Mini-Mental State Examination as screening instruments for cognitive impairment: item analyses and threshold scores. Dement Geriatr Cogn Disord 2011;31:126-131.
42.
Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M: Clinical determinants of poststroke dementia. Stroke 1998;29:75-81.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.